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Background 
Gluten sensitivity and the incidence of Celiac 
disease are ever increasing. The aim was to 
measure the effectiveness of an enzyme based 
dietary supplement on the reduction of symptoms 
encountered upon the consumption of gluten. 
Results 
The data showed a statistically significant 
improvement when compared to the placebo group 
in the following categories: pain, bloating, emptying 
of bowels, hunger pains, rumbling of stomach, lower 
energy levels, headaches, and food cravings. There 
was no statistically signficant improvement in the 
following symptoms: comfort, nausea, and loss of 
appetite.
Conclusion 
Overall, the dietary supplement, Glutalytic, reduced 
many of the symptoms that are encountered upon 
the consumption of gluten.
Introduction 
Gluten is the most important protein component of 
several grains, most notably wheat, rye, and barley. 
These grains are the basis for a range of flour and 
wheat derived products consumed throughout 
the world. In some individuals, gluten components 
cause significant gastrointestinal distress and 
other symptoms. Non-Celiac gluten sensitivity 
is a syndrome characterized by gastrointestinal 
and extraintestinal symptoms occurring within 
a few hours to days after the ingestion of gluten 
and rapidly improving after gluten withdrawal. 
Celiac disease, on the other hand, is classified as 
a genetically linked autoimmune disorder that 
damages the lining of the small intestine and 
prevents it from absorbing parts of food that are 
important for staying healthy. The damage is due to 
a reaction to eating gluten, which is found in wheat, 
barley, rye, and possibly oats.[1-3]
Non-Celiac gluten sensitivity and Celiac disease 
appear to be different due to epidemiologic and 
pathogenetic aspects. Although non-Celiac gluten 
sensitivity prevalence is still poorly defined in 
society, it is thought to be more frequent than Celiac 
disease. The Center of Celiac Research estimates 
that approximately six percent of the U.S. population 
suffers from gluten sensitivity, while the prevalence 
of Celiac disease is approximately one percent of the 
population in developed and developing countries. 
Due to the ever increasing prevalence of gluten 
sensitivity and Celiac disease, there is ongoing 
research on the subject. There is currently no cure or 
treatment outside of a gluten free diet. [2,4]
The purpose of this double-blind, randomized, 
placebo controlled study is to determine if a dietary 
supplement, namely Glutalytic, included with a 
normal diet results in reduced symptoms of gluten 
intolerance in a standard population, as compared 
to the placebo group. For those who are gluten 
sensitive, the hope is to enable them to lead a normal 
life without any food restrictions by incorporating 
the dietary supplement into their daily regimen. The 
dietary supplement should aid in the breakdown of 
the gluten complex to help minimize the symptoms. 
For those diagnosed with Celiac disease, the goal 
is to minimize the risk of persistent or recurring 
symptoms due to contamination through the 
crossover effect, thus giving the individuals peace of 
mind when eating away from home. 
Methods
Questionnaire Design - The questionnaire used in 
this clinical was a modified version of the Internal 
Review Board (IRB) approved, Celiac disease-
specific symptom index which was developed and 
validated by Daniel A. Leffler and his colleagues. The 
questionnaire was modified to account for non-celiac 
gluten sensitivity instead of narrowing only on Celiac 
sensitivity, and was designed to cover a spectrum 
of symptoms that could occur upon the ingestion of 
gluten. [1]
Clinical Design - This survey was administered to 
the entire group of individuals prior to beginning 
the supplement regimen. In conjunction with the 
Glutalytic Clinical Trial for Normal Consumption
of Gluten Containing Foods 
questionnaire, questions regarding the participants’ 
demographics were also completed. The participants 
were not asked to change their diets in any way. 
The clinical was designed for twenty individuals 
and the data presented represents the eleven 
participants who achieved full completion of the 
clinical. Individuals proceeded to ingest a dosage of 
the placebo or Glutalytic with every meal for a week. 
During this time, the participants maintained a meal 
log of everything they ingested. After seven days, 
the participants completed the questionnaire. 
 
Results
Sample frequency was calculated using Microsoft 
Excel 2010 (Table 1, 2, 3) and samples were analyzed 
using IBM SPSS Statistics for the Wilcoxon Signed-
rank test and descriptive statistics (Table 2, 3). The 
level of significance (α) was chosen to be 5%. Initially 
frequencies of responses were calculated, followed 
by the Wilcoxon Signed-rank test in order to see 
if there was any improvement on a question by 
question basis between subjects. 
The results of the initial questionnaire were tallied 
and converted into percentages to be used as a 
control against the data gathered during the placebo 
time as well as the dietary supplement regimen. This 
data is exhibited in Table 1.
To examine the placebo effect, the raw data 
gathered at the end of week two were converted into 
percentages. This can be viewed in Table 2. 
To determine the effectiveness of the dietary 
supplement, Glutalytic, the raw data was transformed 
into percentages and displayed in Table 3. 
Table 1 
Frequency of answers to questionnaire given before both placebo and Glutalytic.
Before Regimen
Question None of
the time
A little of 
the time
Some of 
the time
Most of 
the time
All of 
the time
1.    Have you been bothered by pain or discomfort in the upper 
abdomen or the pit of the stomach during the past 4 weeks?
18% 55% 27% 0% 0%
2.   Have you been bothered by nausea during the past 4 weeks? 82% 9% 9% 0% 0%
3.   Have you been bothered by rumbling in your stomach during the 
past 4 weeks?
0% 45% 55% 0% 0%
4.   Has your stomach felt bloated during the past 4 weeks? 0% 55% 36% 9% 0%
5.   When going on the toilet, have you had the sensation of not 
completely emptying your bowels during the past 4 weeks?
27% 45% 18% 9% 0%
6.   Have you been bothered by hunger pains during the past 4 weeks? 9% 64% 27% 0% 0%
7.   Have you been bothered by low energy during the past 4 weeks? 9% 27% 64% 0% 0%
8.   Have you been bothered by headaches during the past 4 weeks? 36% 36% 18% 9% 0%
9.   Have you had food cravings in the last 4 weeks? 18% 36% 9% 36% 0%
10. Have you had a loss of appetite during the past 4 weeks? 36% 64% 0% 0% 0%
Question Excellent Good Fair Poor Terrible
11. Overall, how is your health? 18% 82% 0% 0% 0%
Question Excellent Good Fair Poor Terrible
12. How much more physical pain have you had during the past 4 weeks? 55% 36% 9% 0% 0%
Question Strongly
agree
Somewhat
agree
Neither 
agree nor
disagree 
Somewhat
disagree
Strongly
disagree
13. I am comfortable 18% 73% 9% 0% 0%
14. I am as healthy as anybody I know 55% 27% 18% 0% 0%
Table 2 
Frequency of questionnaire response after placebo was given. 
Table 3 
Frequency of questionnaire response after regimen was given. Frequencies which differed from the 
“before-regimen questionnaire” statistically (p<0.05) are indicated via *. Questions which additionally 
did not differ between the pre-regimen and placebo group are indicated with**.
Question None of
the time
A little of 
the time
Some of 
the time
Most of 
the time
All of 
the time
1.    Have you been bothered by pain or discomfort in the upper 
abdomen or the pit of the stomach during the past 4 weeks?
27% 18% 55% 0% 0%
2.   Have you been bothered by nausea during the past 4 weeks? 55% 27% 18% 0% 0%
3.   Have you been bothered by rumbling in your stomach during the 
past 4 weeks?
18% 64% 18% 0% 0%
4.   Has your stomach felt bloated during the past 4 weeks? 0% 73% 9% 18% 0%
5.   When going on the toilet, have you had the sensation of not 
completely emptying your bowels during the past 4 weeks?
55% 18% 18% 9% 0%
6.   Have you been bothered by hunger pains during the past 4 weeks? 55% 36% 9% 0% 0%
7.   Have you been bothered by low energy during the past 4 weeks? 9% 27% 64% 0% 0%
8.   Have you been bothered by headaches during the past 4 weeks? 55% 36% 0% 9% 0%
9.   Have you had food cravings in the last 4 weeks? 18% 18% 55% 9% 0%
10. Have you had a loss of appetite during the past 4 weeks? 73% 27% 0% 0% 0%
Question Excellent Good Fair Poor Terrible
11. Overall, how is your health? 18% 82% 0% 0% 0%
Question Excellent Good Fair Poor Terrible
12. How much more physical pain have you had during the past 4 weeks? 9% 91% 0% 0% 0%
Question Strongly
agree
Somewhat
agree
Neither 
agree nor
disagree 
Somewhat
disagree
Strongly
disagree
13. I am comfortable 9% 82% 9% 0% 0%
14. I am as healthy as anybody I know 18% 73% 9% 0% 0%
Question None of
the time
A little of 
the time
Some of 
the time
Most of 
the time
All of 
the time
1.    Have you been bothered by pain or discomfort in the upper 
abdomen or the pit of the stomach during the past 4 weeks?
36% 64% 0% 0% 0%
2.   Have you been bothered by nausea during the past 4 weeks? 91% 9% 0% 0% 0%
3.   Have you been bothered by rumbling in your stomach during the 
past 4 weeks?
45% 45% 9% 0% 0%
4.   Has your stomach felt bloated during the past 4 weeks? 18% 73% 9% 0% 0%
5.   When going on the toilet, have you had the sensation of not 
completely emptying your bowels during the past 4 weeks?
64% 36% 0% 0% 0%
6.   Have you been bothered by hunger pains during the past 4 weeks? 73% 27% 0% 0% 0%
7.   Have you been bothered by low energy during the past 4 weeks? 36% 45% 18% 0% 0%
8.   Have you been bothered by headaches during the past 4 weeks? 64% 27% 9% 0% 0%
9.   Have you had food cravings in the last 4 weeks? 36% 55% 0% 9% 0%
10. Have you had a loss of appetite during the past 4 weeks? 64% 18% 18% 0% 0%
Question Excellent Good Fair Poor Terrible
11. Overall, how is your health? 64% 27% 9% 0% 0%
Question Excellent Good Fair Poor Terrible
12. How much more physical pain have you had during the past 4 weeks? 64% 36% 0% 0% 0%
Question Strongly
agree
Somewhat
agree
Neither 
agree nor
disagree 
Somewhat
disagree
Strongly
disagree
13. I am comfortable 36% 55% 9% 0% 0%
14. I am as healthy as anybody I know 45% 45% 9% 0% 0%
After Placebo
After Glutalytic Regimen
n Initial Questionnaire  n Placebo  n Glutalytic
Discussion
As was expected, the highest frequency of 
symptoms occurred prior to the clinical, then there 
was a slight placebo effect vs. the initial results and 
compared to the Glutalytic results. When Glutalytic 
was administered, the participants exhibited the 
least amount of symptoms (Figure 1). The frequency, 
and severity of all of the symptoms were reduced 
when Glutalytic was administered. 
While there were numerous symptoms that were 
reduced by Glutalytic, many were also reduced by 
the placebo; for the purposes of this study only 
those symptoms that were reduced by Glutalytic, 
while not being reduced by the placebo will be 
examined. These symptoms included pain in the 
upper abdomen, feeling bloated, trouble emptying 
bowls, and food cravings (Table 3). 
 
Symptoms that were reduced by both the 
placebo and Glutalytic included: rumbling of the 
stomach, hunger pains, lower energy levels, and 
headaches. The comparison of the placebo effect 
to Glutalytic can be seen in Figure 2. Overall the 
dietary supplement reduced many of the symptoms 
including: pain in the abdominal area, rumbling of 
the stomach, feeling bloated, trouble emptying 
bowels, hunger pains, lower energy levels, headaches 
and food cravings. 
Although it was not statistically significant, the 
placebo group saw an increase in pain compared 
to the pre-regimen. The pain anomaly cannot be 
explained without further investigation.
It can be concluded that while Glutalytic cannot 
completely diminish the symptoms associated with 
gluten sensitivity, it can reduce the frequency and 
severity. 
Figure 1. Direct Comparison of the Three 
Questionnaires
Figure 2. Changes from the Initial Questionnaire to 
the Placebo and Glutalytic
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